AP Biosciences（6945）株式概要APバイオサイエンシズ社は臨床段階にあるバイオ医薬品会社で、アンメット・メディカル・ニーズを満たす二重特異性抗体医薬品の研究開発を行っています。 詳細6945 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析収益が 100 万ドル未満 ( NT$0 )過去5年間で収益は年間17.8%減少しました。 TW市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見る6945 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW490,132 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG490,132 investors already sharing narrativesYour Fair ValueNT$Current PriceNT$112.00該当なし内在価値ディスカウントEst. Revenue$PastFuture-459m105m2016201920222025202620282031Revenue NT$1.0Earnings NT$0.2AdvancedSet Fair ValueView all narrativesAP Biosciences, Inc. 競合他社AcepodiaSymbol: TPEX:6976Market cap: NT$7.8bAdimmuneSymbol: TWSE:4142Market cap: NT$7.4bTCM Biotech InternationalSymbol: TWSE:4169Market cap: NT$15.9bElixiron Immunotherapeutics (Cayman)Symbol: TPEX:7871Market cap: NT$12.3b価格と性能株価の高値、安値、推移の概要AP Biosciences過去の株価現在の株価NT$112.0052週高値NT$236.0052週安値NT$52.50ベータ-0.451ヶ月の変化9.80%3ヶ月変化-42.42%1年変化104.38%3年間の変化42.31%5年間の変化n/aIPOからの変化42.31%最新ニュースNew Risk • Jun 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m.お知らせ • Apr 01AP Biosciences Inc has filed an IPO in the amount of TWD 1.2562 billion.AP Biosciences Inc has filed an IPO in the amount of TWD 1.2562 billion. Security Name: Shares Securities Offered: 11,420,000 Price\Range: TWD 110お知らせ • Feb 26AP Biosciences Inc, Annual General Meeting, May 20, 2026AP Biosciences Inc, Annual General Meeting, May 20, 2026. Location: 1 floor no,508, sec.7 chung hsiao e. rd., nangang district, taipei city TaiwanBoard Change • Dec 13Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Director Ya-Chi Chen was the last director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 29AP Biosciences Presents Preclinical Data on P95her/Cd137 T-Cell Engager At American Association of Cancer Research Annual MeetingAP Biosciences announced the presentation of new preclinical data for its lead asset, AP402, at the 2025 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California. The data, presented in a poster titled "AP402, a bispecific antibody targeting p95HER2 and CD137, shows potent antitumor activity," highlight the therapeutic potential of AP402 to address treatment-resistant HER2-positive cancers through conditional T-cell engagement. Results Summary: Specificity for p95HER2: AP402 demonstrates high-affinity binding to p95HER2, confirming its selectivity for the truncated isoform over full-length HER2. T-cell Activation: In co-culture assays, AP402 promoted robust IFN-g secretion from T cells, with activity relating to p95HER2 expression on target cells. Compared to combination treatments with individual parent antibodies, AP402 showed synergistic T-cell activation. Activation Across Multiple Cell Lines: AP402 induced strong IFN-g responses in multiple p95HER2-expressing cancer cell lines (e.g., SK-OV-3), demonstrating its potential applicability across tumor types. Antibody-Dependent Cellular Cytotoxicity (ADCC): AP402 induced dose-dependent ADCC activity in p95HER2- expressing MDA-MB-231 cells using CD16-NK-92MI effector cells. Cytotoxicity levels were positively related with p95HER2 expression. Pharmacokinetics and Toxicology in Non-Human Primates (NHPs): In cynomolgus monkeys, AP402 demonstrated a favorable pharmacokinetic profile and was well tolerated up to 100 mg/kg with no observed adverse effects at the highest dose. All findings reversed during the recovery phase. In conclusion, the preclinical data show that AP402 effectively engages innate and adaptive immune responses, demonstrates robust antitumor activity in p95HER2 -expressing tumor models, and is well tolerated in non-human primates. These findings support the continued development of AP402, which recently entered clinical evaluation in Australia (NCT06669975). AP402 is a first-in-class bispecific antibody developed by AP Biosciences to target p95HER2, a truncated variant of HER2 associated with resistance to Herceptin and poorer prognosis. This variant is present in approximately 30-40% of HER2-positive breast cancer patients. By leveraging p95HER2 recognition to cluster CD137, the design enables localized T-cell activation within the tumor microenvironment, helping to minimize systemic cytokine-related toxicity. The binding domains for p95HER2 and CD 137 are strategically positioned on oppositeends to enhance bridging between HER2 variant-expressing cancer cells and CD137-expressing T-cells, ensuring efficient immune cell recruitment without spatial hindrance. This novel mechanism has positioned AP402 as a promising therapeutic approach to addressing tumors that have developed resistance to traditional anti-HER2 therapies, offering potential new hope for patients with refractory/recurrent cancers.お知らせ • Apr 23AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer PatientsAP Biosciences announced that it has dosed the first patient in its Phase 1 study evaluating AP402, a potential first-in-class, next generation T cell engager targeting CD137 and p95HER2 in patients relapsed/refractory to anti-HER2 treatment. The Phase 1 clinical trial, currently taking place in Australia, is designed to evaluate the safety, tolerability, and preliminary efficacy of AP402 in HER2+ patients with advanced solid tumors, including breast cancer. The following dose expansion phase of the study may include clinical sites in Taiwan, South Korea and the United States. AP402-101 (NCT06669975), is a multi-center, open-label Phase 1 trial, enrolling up to 85 patients divided in two parts: a dose-escalation phase to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D), followed by a dose-expansion phase targeting specific HER2-positive tumor types. Primary endpoints of the study include safety and tolerability, while secondary endpoints will evaluate objective response rate (ORR), disease control rate (DCR), and pharmacokinetic (PK) parameters. Exploratory endpoints will assess pharmacodynamic biomarkers and immunogenicity.最新情報をもっと見るRecent updatesNew Risk • Jun 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m.お知らせ • Apr 01AP Biosciences Inc has filed an IPO in the amount of TWD 1.2562 billion.AP Biosciences Inc has filed an IPO in the amount of TWD 1.2562 billion. Security Name: Shares Securities Offered: 11,420,000 Price\Range: TWD 110お知らせ • Feb 26AP Biosciences Inc, Annual General Meeting, May 20, 2026AP Biosciences Inc, Annual General Meeting, May 20, 2026. Location: 1 floor no,508, sec.7 chung hsiao e. rd., nangang district, taipei city TaiwanBoard Change • Dec 13Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Director Ya-Chi Chen was the last director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 29AP Biosciences Presents Preclinical Data on P95her/Cd137 T-Cell Engager At American Association of Cancer Research Annual MeetingAP Biosciences announced the presentation of new preclinical data for its lead asset, AP402, at the 2025 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California. The data, presented in a poster titled "AP402, a bispecific antibody targeting p95HER2 and CD137, shows potent antitumor activity," highlight the therapeutic potential of AP402 to address treatment-resistant HER2-positive cancers through conditional T-cell engagement. Results Summary: Specificity for p95HER2: AP402 demonstrates high-affinity binding to p95HER2, confirming its selectivity for the truncated isoform over full-length HER2. T-cell Activation: In co-culture assays, AP402 promoted robust IFN-g secretion from T cells, with activity relating to p95HER2 expression on target cells. Compared to combination treatments with individual parent antibodies, AP402 showed synergistic T-cell activation. Activation Across Multiple Cell Lines: AP402 induced strong IFN-g responses in multiple p95HER2-expressing cancer cell lines (e.g., SK-OV-3), demonstrating its potential applicability across tumor types. Antibody-Dependent Cellular Cytotoxicity (ADCC): AP402 induced dose-dependent ADCC activity in p95HER2- expressing MDA-MB-231 cells using CD16-NK-92MI effector cells. Cytotoxicity levels were positively related with p95HER2 expression. Pharmacokinetics and Toxicology in Non-Human Primates (NHPs): In cynomolgus monkeys, AP402 demonstrated a favorable pharmacokinetic profile and was well tolerated up to 100 mg/kg with no observed adverse effects at the highest dose. All findings reversed during the recovery phase. In conclusion, the preclinical data show that AP402 effectively engages innate and adaptive immune responses, demonstrates robust antitumor activity in p95HER2 -expressing tumor models, and is well tolerated in non-human primates. These findings support the continued development of AP402, which recently entered clinical evaluation in Australia (NCT06669975). AP402 is a first-in-class bispecific antibody developed by AP Biosciences to target p95HER2, a truncated variant of HER2 associated with resistance to Herceptin and poorer prognosis. This variant is present in approximately 30-40% of HER2-positive breast cancer patients. By leveraging p95HER2 recognition to cluster CD137, the design enables localized T-cell activation within the tumor microenvironment, helping to minimize systemic cytokine-related toxicity. The binding domains for p95HER2 and CD 137 are strategically positioned on oppositeends to enhance bridging between HER2 variant-expressing cancer cells and CD137-expressing T-cells, ensuring efficient immune cell recruitment without spatial hindrance. This novel mechanism has positioned AP402 as a promising therapeutic approach to addressing tumors that have developed resistance to traditional anti-HER2 therapies, offering potential new hope for patients with refractory/recurrent cancers.お知らせ • Apr 23AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer PatientsAP Biosciences announced that it has dosed the first patient in its Phase 1 study evaluating AP402, a potential first-in-class, next generation T cell engager targeting CD137 and p95HER2 in patients relapsed/refractory to anti-HER2 treatment. The Phase 1 clinical trial, currently taking place in Australia, is designed to evaluate the safety, tolerability, and preliminary efficacy of AP402 in HER2+ patients with advanced solid tumors, including breast cancer. The following dose expansion phase of the study may include clinical sites in Taiwan, South Korea and the United States. AP402-101 (NCT06669975), is a multi-center, open-label Phase 1 trial, enrolling up to 85 patients divided in two parts: a dose-escalation phase to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D), followed by a dose-expansion phase targeting specific HER2-positive tumor types. Primary endpoints of the study include safety and tolerability, while secondary endpoints will evaluate objective response rate (ORR), disease control rate (DCR), and pharmacokinetic (PK) parameters. Exploratory endpoints will assess pharmacodynamic biomarkers and immunogenicity.お知らせ • Apr 22AP Biosciences to Present New Preclinical Data at American Association of Cancer Research Annual MeetingAP Biosciences announced that it will present a preclinical abstract in a poster presentation at the upcoming American Association for Cancer Research (AACR) Association Annual Meeting, taking place in Chicago, IL, April 25- 30, 2025. The data will showcase the potential of AP402, a first-in-class, next generation T cell engager targeting CD137 and p95HER2 in in-vivo and in vitro studies. AP402 recently received IND clearance to begin clinical trials in Australia this past February.New Risk • Apr 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.12b (US$94.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (NT$32m revenue, or US$980k). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (NT$3.12b market cap, or US$94.7m).New Risk • Apr 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.8% average weekly change). Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (NT$32m revenue, or US$976k). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).お知らせ • Mar 26AP Biosciences Inc, Annual General Meeting, Jun 20, 2025AP Biosciences Inc, Annual General Meeting, Jun 20, 2025, at 09:30 Taipei Standard Time. Location: 1 floor no,508, sec.7 chung hsiao e. rd., nangang district, taipei city TaiwanNew Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (NT$32m revenue, or US$980k). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (NT$32m revenue, or US$978k).New Risk • Aug 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 31% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (31% increase in shares outstanding). Revenue is less than US$5m (NT$32m revenue, or US$1.0m).New Risk • Jul 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.22b (US$98.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$32m revenue, or US$981k). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (NT$3.22b market cap, or US$98.1m).New Risk • Dec 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.13b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (NT$3.13b market cap, or US$99.4m).Board Change • Jul 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CEO & Director Jeng-Horng Her was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.株主還元6945TW BiotechsTW 市場7D6.7%3.9%-3.1%1Y104.4%86.2%97.8%株主還元を見る業界別リターン: 6945過去 1 年間で86.2 % の収益を上げたTW Biotechs業界を上回りました。リターン対市場: 6945過去 1 年間で97.8 % の収益を上げたTW市場を上回りました。価格変動Is 6945's price volatile compared to industry and market?6945 volatility6945 Average Weekly Movement10.1%Biotechs Industry Average Movement6.3%Market Average Movement6.5%10% most volatile stocks in TW Market12.0%10% least volatile stocks in TW Market2.6%安定した株価: 6945の株価は、 TW市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 6945の weekly volatility ( 10% ) は過去 1 年間安定していますが、依然としてTWの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2013n/aJeng-Horng Herwww.apbioinc.com臨床段階のバイオ医薬品企業であるAPバイオサイエンシズ社は、アンメット・メディカル・ニーズを満たす二重特異性抗体医薬品の研究開発を行っている。新生血管性加齢黄斑変性の治療薬として第III相臨床試験中のIBI302、固形癌の治療薬として第I相臨床試験中のAP505、非小細胞肺癌、頭頸部扁平上皮癌、食道扁平上皮癌の治療薬として第I相臨床試験中のAP203を開発している；乳がん患者を対象とした前臨床研究段階にあるAP402、肺がん、膵臓がん、膀胱がん、卵巣がん、その他の固形がんを対象とした前臨床研究段階にあるAP601がある。同社は2013年に設立され、台湾の台北市に本社を置いている。もっと見るAP Biosciences, Inc. 基礎のまとめAP Biosciences の収益と売上を時価総額と比較するとどうか。6945 基礎統計学時価総額NT$10.86b収益（TTM）-NT$459.05m売上高(TTM)n/a0.0xP/Sレシオ-23.7xPER（株価収益率6945 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計6945 損益計算書（TTM）収益NT$0売上原価NT$0売上総利益NT$0その他の費用NT$459.05m収益-NT$459.05m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-4.73グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%6945 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/10 15:24終値2026/07/09 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋AP Biosciences, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m.
お知らせ • Apr 01AP Biosciences Inc has filed an IPO in the amount of TWD 1.2562 billion.AP Biosciences Inc has filed an IPO in the amount of TWD 1.2562 billion. Security Name: Shares Securities Offered: 11,420,000 Price\Range: TWD 110
お知らせ • Feb 26AP Biosciences Inc, Annual General Meeting, May 20, 2026AP Biosciences Inc, Annual General Meeting, May 20, 2026. Location: 1 floor no,508, sec.7 chung hsiao e. rd., nangang district, taipei city Taiwan
Board Change • Dec 13Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Director Ya-Chi Chen was the last director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 29AP Biosciences Presents Preclinical Data on P95her/Cd137 T-Cell Engager At American Association of Cancer Research Annual MeetingAP Biosciences announced the presentation of new preclinical data for its lead asset, AP402, at the 2025 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California. The data, presented in a poster titled "AP402, a bispecific antibody targeting p95HER2 and CD137, shows potent antitumor activity," highlight the therapeutic potential of AP402 to address treatment-resistant HER2-positive cancers through conditional T-cell engagement. Results Summary: Specificity for p95HER2: AP402 demonstrates high-affinity binding to p95HER2, confirming its selectivity for the truncated isoform over full-length HER2. T-cell Activation: In co-culture assays, AP402 promoted robust IFN-g secretion from T cells, with activity relating to p95HER2 expression on target cells. Compared to combination treatments with individual parent antibodies, AP402 showed synergistic T-cell activation. Activation Across Multiple Cell Lines: AP402 induced strong IFN-g responses in multiple p95HER2-expressing cancer cell lines (e.g., SK-OV-3), demonstrating its potential applicability across tumor types. Antibody-Dependent Cellular Cytotoxicity (ADCC): AP402 induced dose-dependent ADCC activity in p95HER2- expressing MDA-MB-231 cells using CD16-NK-92MI effector cells. Cytotoxicity levels were positively related with p95HER2 expression. Pharmacokinetics and Toxicology in Non-Human Primates (NHPs): In cynomolgus monkeys, AP402 demonstrated a favorable pharmacokinetic profile and was well tolerated up to 100 mg/kg with no observed adverse effects at the highest dose. All findings reversed during the recovery phase. In conclusion, the preclinical data show that AP402 effectively engages innate and adaptive immune responses, demonstrates robust antitumor activity in p95HER2 -expressing tumor models, and is well tolerated in non-human primates. These findings support the continued development of AP402, which recently entered clinical evaluation in Australia (NCT06669975). AP402 is a first-in-class bispecific antibody developed by AP Biosciences to target p95HER2, a truncated variant of HER2 associated with resistance to Herceptin and poorer prognosis. This variant is present in approximately 30-40% of HER2-positive breast cancer patients. By leveraging p95HER2 recognition to cluster CD137, the design enables localized T-cell activation within the tumor microenvironment, helping to minimize systemic cytokine-related toxicity. The binding domains for p95HER2 and CD 137 are strategically positioned on oppositeends to enhance bridging between HER2 variant-expressing cancer cells and CD137-expressing T-cells, ensuring efficient immune cell recruitment without spatial hindrance. This novel mechanism has positioned AP402 as a promising therapeutic approach to addressing tumors that have developed resistance to traditional anti-HER2 therapies, offering potential new hope for patients with refractory/recurrent cancers.
お知らせ • Apr 23AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer PatientsAP Biosciences announced that it has dosed the first patient in its Phase 1 study evaluating AP402, a potential first-in-class, next generation T cell engager targeting CD137 and p95HER2 in patients relapsed/refractory to anti-HER2 treatment. The Phase 1 clinical trial, currently taking place in Australia, is designed to evaluate the safety, tolerability, and preliminary efficacy of AP402 in HER2+ patients with advanced solid tumors, including breast cancer. The following dose expansion phase of the study may include clinical sites in Taiwan, South Korea and the United States. AP402-101 (NCT06669975), is a multi-center, open-label Phase 1 trial, enrolling up to 85 patients divided in two parts: a dose-escalation phase to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D), followed by a dose-expansion phase targeting specific HER2-positive tumor types. Primary endpoints of the study include safety and tolerability, while secondary endpoints will evaluate objective response rate (ORR), disease control rate (DCR), and pharmacokinetic (PK) parameters. Exploratory endpoints will assess pharmacodynamic biomarkers and immunogenicity.
New Risk • Jun 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m.
お知らせ • Apr 01AP Biosciences Inc has filed an IPO in the amount of TWD 1.2562 billion.AP Biosciences Inc has filed an IPO in the amount of TWD 1.2562 billion. Security Name: Shares Securities Offered: 11,420,000 Price\Range: TWD 110
お知らせ • Feb 26AP Biosciences Inc, Annual General Meeting, May 20, 2026AP Biosciences Inc, Annual General Meeting, May 20, 2026. Location: 1 floor no,508, sec.7 chung hsiao e. rd., nangang district, taipei city Taiwan
Board Change • Dec 13Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Director Ya-Chi Chen was the last director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 29AP Biosciences Presents Preclinical Data on P95her/Cd137 T-Cell Engager At American Association of Cancer Research Annual MeetingAP Biosciences announced the presentation of new preclinical data for its lead asset, AP402, at the 2025 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California. The data, presented in a poster titled "AP402, a bispecific antibody targeting p95HER2 and CD137, shows potent antitumor activity," highlight the therapeutic potential of AP402 to address treatment-resistant HER2-positive cancers through conditional T-cell engagement. Results Summary: Specificity for p95HER2: AP402 demonstrates high-affinity binding to p95HER2, confirming its selectivity for the truncated isoform over full-length HER2. T-cell Activation: In co-culture assays, AP402 promoted robust IFN-g secretion from T cells, with activity relating to p95HER2 expression on target cells. Compared to combination treatments with individual parent antibodies, AP402 showed synergistic T-cell activation. Activation Across Multiple Cell Lines: AP402 induced strong IFN-g responses in multiple p95HER2-expressing cancer cell lines (e.g., SK-OV-3), demonstrating its potential applicability across tumor types. Antibody-Dependent Cellular Cytotoxicity (ADCC): AP402 induced dose-dependent ADCC activity in p95HER2- expressing MDA-MB-231 cells using CD16-NK-92MI effector cells. Cytotoxicity levels were positively related with p95HER2 expression. Pharmacokinetics and Toxicology in Non-Human Primates (NHPs): In cynomolgus monkeys, AP402 demonstrated a favorable pharmacokinetic profile and was well tolerated up to 100 mg/kg with no observed adverse effects at the highest dose. All findings reversed during the recovery phase. In conclusion, the preclinical data show that AP402 effectively engages innate and adaptive immune responses, demonstrates robust antitumor activity in p95HER2 -expressing tumor models, and is well tolerated in non-human primates. These findings support the continued development of AP402, which recently entered clinical evaluation in Australia (NCT06669975). AP402 is a first-in-class bispecific antibody developed by AP Biosciences to target p95HER2, a truncated variant of HER2 associated with resistance to Herceptin and poorer prognosis. This variant is present in approximately 30-40% of HER2-positive breast cancer patients. By leveraging p95HER2 recognition to cluster CD137, the design enables localized T-cell activation within the tumor microenvironment, helping to minimize systemic cytokine-related toxicity. The binding domains for p95HER2 and CD 137 are strategically positioned on oppositeends to enhance bridging between HER2 variant-expressing cancer cells and CD137-expressing T-cells, ensuring efficient immune cell recruitment without spatial hindrance. This novel mechanism has positioned AP402 as a promising therapeutic approach to addressing tumors that have developed resistance to traditional anti-HER2 therapies, offering potential new hope for patients with refractory/recurrent cancers.
お知らせ • Apr 23AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer PatientsAP Biosciences announced that it has dosed the first patient in its Phase 1 study evaluating AP402, a potential first-in-class, next generation T cell engager targeting CD137 and p95HER2 in patients relapsed/refractory to anti-HER2 treatment. The Phase 1 clinical trial, currently taking place in Australia, is designed to evaluate the safety, tolerability, and preliminary efficacy of AP402 in HER2+ patients with advanced solid tumors, including breast cancer. The following dose expansion phase of the study may include clinical sites in Taiwan, South Korea and the United States. AP402-101 (NCT06669975), is a multi-center, open-label Phase 1 trial, enrolling up to 85 patients divided in two parts: a dose-escalation phase to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D), followed by a dose-expansion phase targeting specific HER2-positive tumor types. Primary endpoints of the study include safety and tolerability, while secondary endpoints will evaluate objective response rate (ORR), disease control rate (DCR), and pharmacokinetic (PK) parameters. Exploratory endpoints will assess pharmacodynamic biomarkers and immunogenicity.
お知らせ • Apr 22AP Biosciences to Present New Preclinical Data at American Association of Cancer Research Annual MeetingAP Biosciences announced that it will present a preclinical abstract in a poster presentation at the upcoming American Association for Cancer Research (AACR) Association Annual Meeting, taking place in Chicago, IL, April 25- 30, 2025. The data will showcase the potential of AP402, a first-in-class, next generation T cell engager targeting CD137 and p95HER2 in in-vivo and in vitro studies. AP402 recently received IND clearance to begin clinical trials in Australia this past February.
New Risk • Apr 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.12b (US$94.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (NT$32m revenue, or US$980k). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (NT$3.12b market cap, or US$94.7m).
New Risk • Apr 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.8% average weekly change). Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (NT$32m revenue, or US$976k). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
お知らせ • Mar 26AP Biosciences Inc, Annual General Meeting, Jun 20, 2025AP Biosciences Inc, Annual General Meeting, Jun 20, 2025, at 09:30 Taipei Standard Time. Location: 1 floor no,508, sec.7 chung hsiao e. rd., nangang district, taipei city Taiwan
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (NT$32m revenue, or US$980k). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (NT$32m revenue, or US$978k).
New Risk • Aug 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 31% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (31% increase in shares outstanding). Revenue is less than US$5m (NT$32m revenue, or US$1.0m).
New Risk • Jul 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.22b (US$98.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$32m revenue, or US$981k). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (NT$3.22b market cap, or US$98.1m).
New Risk • Dec 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.13b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (NT$3.13b market cap, or US$99.4m).
Board Change • Jul 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CEO & Director Jeng-Horng Her was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
